IN2014DN10259A - - Google Patents
Info
- Publication number
- IN2014DN10259A IN2014DN10259A IN10259DEN2014A IN2014DN10259A IN 2014DN10259 A IN2014DN10259 A IN 2014DN10259A IN 10259DEN2014 A IN10259DEN2014 A IN 10259DEN2014A IN 2014DN10259 A IN2014DN10259 A IN 2014DN10259A
- Authority
- IN
- India
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Zoology (AREA)
- Virology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Ecology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261651144P | 2012-05-24 | 2012-05-24 | |
| PCT/US2013/042627 WO2013177505A1 (en) | 2012-05-24 | 2013-05-24 | Diabetes biomarkers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN10259A true IN2014DN10259A (enExample) | 2015-08-07 |
Family
ID=49621783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN10259DEN2014 IN2014DN10259A (enExample) | 2012-05-24 | 2014-12-02 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US20130316375A1 (enExample) |
| EP (2) | EP3767295A1 (enExample) |
| JP (5) | JP6312332B2 (enExample) |
| KR (1) | KR102172285B1 (enExample) |
| CN (1) | CN104520707B (enExample) |
| AU (4) | AU2013266145A1 (enExample) |
| CA (1) | CA2874507A1 (enExample) |
| DK (1) | DK2856149T3 (enExample) |
| ES (1) | ES2810227T3 (enExample) |
| IN (1) | IN2014DN10259A (enExample) |
| MX (1) | MX357169B (enExample) |
| WO (1) | WO2013177505A1 (enExample) |
| ZA (1) | ZA201409006B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8735359B2 (en) | 2012-05-24 | 2014-05-27 | Orban Biotech Llc | Combinations of modalities for the treatment of diabetes |
| US20130316375A1 (en) * | 2012-05-24 | 2013-11-28 | Orban Biotech Llc | Diabetes biomarkers |
| CN113138279A (zh) | 2012-06-27 | 2021-07-20 | 法姆制药有限责任公司 | 融合蛋白组合物的应用 |
| GB2523399B (en) | 2014-02-25 | 2019-03-13 | Orban Tihamer | A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence |
| WO2016103390A1 (ja) * | 2014-12-25 | 2016-06-30 | 株式会社日立製作所 | インスリン分泌能分析装置、当該装置を備えるインスリン分泌能分析システム及びインスリン分泌能分析方法 |
| CN105567851A (zh) * | 2016-02-29 | 2016-05-11 | 北京泱深生物信息技术有限公司 | 一种与糖尿病相关的分子标志物 |
| EP3433612B1 (en) * | 2016-03-22 | 2024-10-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and kits of assessing status, risk or prognosis of type 1 diabetes |
| CA3184157A1 (en) | 2020-06-26 | 2021-12-30 | Phaim Pharma Ltd | Psoriasis and other autoimmune diseases antigen immune modulator (aim) therapeutic platform |
| US20240277768A1 (en) | 2021-06-17 | 2024-08-22 | Tihamer Orban | Individualized Cell Therapy Using Patient-Derived Antigen-Specific Regulatory T Cells |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1930415A4 (en) * | 2005-09-30 | 2009-05-13 | Univ Kyoto | DEVELOPMENT OF A SCREENING METHOD FOR A CONNECTABLE COMPOUND FOR IMPROVING THE PRODUCTION OF A REGULATORY T-CELL AND METHOD FOR THE PRODUCTION OF A REGULATORY T-CELL USING AN IMMUNOSUPPRESSIVE MAKROLIDANTIBIOTIC |
| US9176122B2 (en) * | 2008-03-24 | 2015-11-03 | University Of South Florida | Biomarkers for predicting response to immunosuppressive therapy |
| US20100080784A1 (en) * | 2008-09-12 | 2010-04-01 | Torrey Pines Institute For Molecular Studies | Methods for treating cachexia and lymphopenia |
| US20130316375A1 (en) * | 2012-05-24 | 2013-11-28 | Orban Biotech Llc | Diabetes biomarkers |
-
2013
- 2013-03-14 US US13/803,581 patent/US20130316375A1/en not_active Abandoned
- 2013-05-24 EP EP20184212.7A patent/EP3767295A1/en active Pending
- 2013-05-24 KR KR1020147036002A patent/KR102172285B1/ko active Active
- 2013-05-24 AU AU2013266145A patent/AU2013266145A1/en not_active Abandoned
- 2013-05-24 JP JP2015514216A patent/JP6312332B2/ja active Active
- 2013-05-24 ES ES13794110T patent/ES2810227T3/es active Active
- 2013-05-24 EP EP13794110.0A patent/EP2856149B1/en active Active
- 2013-05-24 CN CN201380027247.6A patent/CN104520707B/zh not_active Expired - Fee Related
- 2013-05-24 CA CA2874507A patent/CA2874507A1/en active Pending
- 2013-05-24 WO PCT/US2013/042627 patent/WO2013177505A1/en not_active Ceased
- 2013-05-24 MX MX2014014348A patent/MX357169B/es active IP Right Grant
- 2013-05-24 DK DK13794110.0T patent/DK2856149T3/da active
-
2014
- 2014-12-02 IN IN10259DEN2014 patent/IN2014DN10259A/en unknown
- 2014-12-08 ZA ZA2014/09006A patent/ZA201409006B/en unknown
-
2016
- 2016-06-17 US US15/185,831 patent/US20160299128A1/en not_active Abandoned
-
2018
- 2018-02-19 JP JP2018027381A patent/JP6761827B2/ja not_active Expired - Fee Related
- 2018-12-28 US US16/235,556 patent/US20190137483A1/en not_active Abandoned
-
2019
- 2019-02-07 AU AU2019200824A patent/AU2019200824B2/en not_active Ceased
-
2020
- 2020-09-07 JP JP2020150183A patent/JP2021001899A/ja active Pending
-
2021
- 2021-04-28 AU AU2021202609A patent/AU2021202609A1/en not_active Abandoned
-
2022
- 2022-11-02 JP JP2022175993A patent/JP2023011814A/ja active Pending
-
2023
- 2023-04-27 US US18/140,214 patent/US20230333094A1/en not_active Abandoned
- 2023-08-31 AU AU2023222980A patent/AU2023222980A1/en active Pending
-
2024
- 2024-07-25 JP JP2024120652A patent/JP2024150702A/ja active Pending
-
2025
- 2025-04-10 US US19/175,610 patent/US20250237643A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150022878A (ko) | 2015-03-04 |
| JP2018116061A (ja) | 2018-07-26 |
| CN104520707A (zh) | 2015-04-15 |
| AU2019200824B2 (en) | 2021-06-24 |
| EP2856149A1 (en) | 2015-04-08 |
| US20160299128A1 (en) | 2016-10-13 |
| MX357169B (es) | 2018-06-28 |
| AU2019200824A1 (en) | 2019-04-04 |
| JP2024150702A (ja) | 2024-10-23 |
| JP6312332B2 (ja) | 2018-04-18 |
| AU2021202609A1 (en) | 2021-05-27 |
| JP6761827B2 (ja) | 2020-09-30 |
| EP3767295A1 (en) | 2021-01-20 |
| US20230333094A1 (en) | 2023-10-19 |
| EP2856149A4 (en) | 2016-06-01 |
| MX2014014348A (es) | 2015-06-05 |
| JP2021001899A (ja) | 2021-01-07 |
| KR102172285B1 (ko) | 2020-11-02 |
| US20130316375A1 (en) | 2013-11-28 |
| EP2856149B1 (en) | 2020-07-08 |
| JP2015520378A (ja) | 2015-07-16 |
| DK2856149T3 (da) | 2020-08-17 |
| AU2013266145A1 (en) | 2015-01-15 |
| ES2810227T3 (es) | 2021-03-08 |
| US20250237643A1 (en) | 2025-07-24 |
| JP2023011814A (ja) | 2023-01-24 |
| CA2874507A1 (en) | 2013-11-28 |
| CN104520707B (zh) | 2018-03-27 |
| ZA201409006B (en) | 2016-07-27 |
| US20190137483A1 (en) | 2019-05-09 |
| WO2013177505A1 (en) | 2013-11-28 |
| AU2023222980A1 (en) | 2023-09-21 |